Diabetes Drug Prevents Complications Beyond Blood Sugar
Here’s a breakdown of the key information from the provided text, focusing on the research and its implications:
The Problem:
* Diabetes complications often persist even when blood sugar is well-controlled. This suggests other mechanisms are at play.
* These complications are linked to the buildup of Advanced Glycation End Products (AGEs).
The Research & Findings:
* Researchers have been trying to block AGEs from interacting with RAGE (Receptor for Advanced Glycation End Products) without success.
* This new research focuses on what happens after AGEs bind to RAGE.
* They discovered that RAGE interacts with a protein called DIAPH1.
* DIAPH1 normally has a “brake” engaged, keeping its activity in check.
* When RAGE (bound to AGEs) interacts with DIAPH1,the “brake” is released,leading to potentially harmful cellular consequences.
* Researchers, with the help of structural biologist Alexander Shekhtman, created a detailed model of the RAGE-DIAPH1 interaction.
The Potential Solution:
* The team screened 58,000 molecules to find one that could block the RAGE-DIAPH1 interaction.
* They identified a promising molecule that, in initial mouse experiments, curbed diabetes complications.
In essence, the research suggests a new target (the RAGE-DIAPH1 interaction) for preventing diabetes complications, offering a potential avenue for treatment beyond just managing blood sugar levels.